Medscape Conference Coverage, based on selected sessions at the:

31st Annual San Antonio Breast Cancer Symposium (SABCS)

December 10 - 14, 2008; San Antonio, Texas

This activity is not sanctioned by, nor a part of, the San Antonio Breast Cancer Symposium. Conference news does not receive grant support and is produced independently.

Perspectives

Conference News

  • Breast Cancer Risk Varies by Type of Benign Breast Disease in Young Women

    The risk for breast cancer is increased among women with benign breast disease, especially those with atypical hyperplasia.
    Medscape Medical News, December 22, 2008
  • Chromosome 17 Polysomy Predicts Anthracycline Response

    The search for biomarkers that predict response to anthracycline therapy in breast cancer has discarded 2 previous contenders and identified a new one.
    Medscape Medical News, December 22, 2008
  • Gene Test for Poor Responders to Tamoxifen

    The CYP2D6 gene test identifies poor metabolizers of tamoxifen, who are at greater risk of developing breast cancer recurrences than extensive metabolizers.
    Medscape Medical News, December 18, 2008
  • Six Cycles of Adjuvant Concurrent TAC

    The combined insights of 2 studies suggest that 6 cycles of docetaxel, doxorubicin, and cyclophosphamide are better than 4 cycles.
    Medscape Medical News, December 18, 2008
  • AIs "Somewhat Better" Than Tamoxifen

    A huge meta-analysis shows that aromatase inhibitors (AIS) reduce relapse significantly more than tamoxifen, but there is little or no difference in survival.
    Medscape Medical News, December 17, 2008
  • Do Hormone Supplements Reduce Deaths?

    Two studies of hormone therapy with estrogen plus progestin arrived at different conclusions about the association between the therapy and survival benefit in women with breast cancer.
    Medscape Medical News, December 17, 2008
  • SABCS 2008: Change in Breast Density Predicts Tamoxifen Benefit

    Among women at high risk for breast cancer and who are treated with tamoxifen, a reduction in breast density of 10% or more is an early predictor of which women will benefit from the therapy.
    Medscape Medical News, December 16, 2008
  • Breast Cancer Risk Declines Sharply

    A new analysis from the Women's Health Initiative shows that the increased risk for breast cancer associated with estrogen and progestin supplementation declines markedly after therapy is stopped.
    Medscape Medical News, December 16, 2008
  • SABCS 2008: Improving the Clinical Breast Examination

    A new study demonstrates that when clinicians are asked to focus attention while performing a breast examination, the rate of detection of breast masses increases.
    Medscape Medical News, December 15, 2008
  • HER2-Positive Tumors Need Adjuvant Treatment

    Small and low-grade HER2-postive breast tumors should be treated with adjuvant therapy, according to 2 new studies.
    Medscape Medical News, December 15, 2008
  • Gene Test Better Predicts Breast Cancer Risk

    A new tool detects gene variations that are linked to an increased risk for breast cancer.
    Medscape Medical News, December 15, 2008
  • Zoledronic Acid Directly Affects Breast Cancer

    Preliminary results show that the bisphosphonate, when used with chemotherapy, shrinks the size of the tumor more than chemotherapy alone.
    Medscape Medical News, December 12, 2008
  • Lapatinib Plus Letrozole in Metastatic Breast Cancer

    The combination of lapatinib plus letrozole more than doubled progression-free survival, compared with letrozole alone.
    Medscape Medical News, December 12, 2008
  • Neoadjuvant Trastuzumab

    For locally advanced breast cancer, adding trastuzumab to chemotherapy before surgery almost halved the relative risk for relapse.
    Medscape Medical News, December 12, 2008
Disclaimer

The materials presented here do not reflect the views of Medscape or the companies providing unrestricted educational grants. These materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. All readers or continuing education participants should verify all information and data before treating patients or employing any therapies described in this educational activity.

The materials presented here were prepared by independent authors under the editorial supervision of Medscape and do not represent a publication of the San Antonio Breast Cancer Symposium. These materials and the related activity are not sanctioned by the San Antonio Breast Cancer Symposium or any commercial supporters of the conference and do not constitute an official part of that conference.